LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

Accueil・Liste d'Actions・Immunocore Holdings PLC ADR

Immunocore Holdings PLC ADR

Fermé

28.73 -0.28

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

27.86

Max

29.12

Chiffres clés
By Trading Economics
Revenu	43M 13M
Ventes	29M 107M
BPA	0.25
Marge bénéficiaire	12.139
Employés	524
EBITDA	16M 8.2M

Recommandations
By TipRanks
Recommandations	Achat
Prévisions sur 12 Mois	+124.82% upside

Dividendes
By Dow Jones
Prochains Résultats	6 août 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	17M 1.5B
Ouverture précédente	29.01
Clôture précédente	28.73

Immunocore Holdings PLC ADR Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

29 mai 2026, 23:08 UTC

Acquisitions, Fusions, Rachats

Family Offices Bypass Private Equity and Go Direct -- Barrons.com

29 mai 2026, 23:06 UTC

Acquisitions, Fusions, Rachats

After a Series of Sales, Hims Director Buys Company Shares -- Barrons.com

29 mai 2026, 20:53 UTC

Résultats

Oil Declines Lift Stocks to Fresh Records -- WSJ

29 mai 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

29 mai 2026, 20:33 UTC

Market Talk

Canada Meets Only One of Three Criteria To Declare Recession -- Market Talk

29 mai 2026, 20:11 UTC

Résultats

Okta Stock Soars. What's Stealing the Show From Earnings. -- Barrons.com

29 mai 2026, 19:47 UTC

Résultats

These Were the Best and Worst S&P 500 Stocks in May -- Barrons.com

29 mai 2026, 19:36 UTC

Market Talk

U.S. Natural Gas Futures End Month With Gains -- Market Talk

29 mai 2026, 19:34 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

29 mai 2026, 19:34 UTC

Market Talk

Over Half of Canadian Industries Growing, Undermining Recession Talk -- Market Talk

29 mai 2026, 19:22 UTC

Market Talk

Oil Falls as U.S., Iran Expected to Reach Agreement -- Market Talk

29 mai 2026, 19:05 UTC

Acquisitions, Fusions, Rachats

Universal Music Group Rejects $65 Billion Takeover Bid From Bill Ackman's Pershing Square -- Barrons.com

29 mai 2026, 18:19 UTC

Market Talk

Canada Technical Recession Chatter Rife But Per-Capita GDP Was Up -- Market Talk

29 mai 2026, 18:12 UTC

Acquisitions, Fusions, Rachats

Universal Music Group Rejects $65 Billion Buyout Offer From Bill Ackman -- WSJ

29 mai 2026, 18:11 UTC

Market Talk

Canada Households Reaching Limit at Keeping Spending in Positive Territory -- Market Talk

29 mai 2026, 18:10 UTC

Market Talk

As BTC Long-Term Holders Rise, Short-Term Holders Flee -- Market Talk

29 mai 2026, 17:55 UTC

Résultats

Okta Stock Soars. What's Stealing the Show From Earnings. -- Barrons.com

29 mai 2026, 17:55 UTC

Market Talk

NEAR Protocol Nearly Doubles in May -- Market Talk

29 mai 2026, 17:38 UTC

Market Talk

U.S. Oil Rig Count Rises for Fifth Straight Week -- Market Talk

29 mai 2026, 17:00 UTC

Résultats

Okta Stock Soars After Earnings. Results Aren't the Real Catalyst. -- Barrons.com

29 mai 2026, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

29 mai 2026, 16:20 UTC

Market Talk

Health Care Roundup: Market Talk

29 mai 2026, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

29 mai 2026, 16:02 UTC

Market Talk

Gold Extend Gains as Investors Await U.S.-Iran Deal News -- Market Talk

29 mai 2026, 15:55 UTC

Market Talk

Global Equities Roundup: Market Talk

29 mai 2026, 15:55 UTC

Market Talk

Cryptocurrencies Appear Detached From Stocks -- Market Talk

29 mai 2026, 15:50 UTC

Acquisitions, Fusions, Rachats

Johnson Matthey CEO: Cormetech Acquisition to Drive Growth

29 mai 2026, 15:50 UTC

Acquisitions, Fusions, Rachats

Johnson Matthey CEO: Demand for AI Data Centers Insatiable

29 mai 2026, 15:40 UTC

Market Talk

Kalshi To Launch Crypto Perpetual Futures -- Market Talk

29 mai 2026, 15:20 UTC

Market Talk

Canada's Economy Not Looking All That Bright -- Market Talk

Comparaison

Variation de prix

Immunocore Holdings PLC ADR prévision

Objectif de Prix

By TipRanks

124.82% hausse

Prévisions sur 12 Mois

Moyen 65.13 USD 124.82%

Haut 100 USD

Bas 33 USD

Basé sur 9 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

9 ratings

Achat

Maintien

Vente

Basé sur 9 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Immunocore Holdings PLC ADR

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.